Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

61. Treatment of Low Bone Density or Osteoporosis

Treatment of Low Bone Density or Osteoporosis Treatment of Low Bone Density or Osteoporosis -- Clinical Recommendation Welcome Search Search Specify your search AAFP.org Patient Care Clinical Practice Guideline Treatment of Low Bone Density or Osteoporosis Treatment of Low Bone Density or Osteoporosis (Endorsed, April 2017) The guideline, Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women , was developed by the American College of Physicians and was endorsed (...) by the American Academy of Family Physicians. Key Recommendations Pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab should be prescribed for women with osteoporosis to reduce the risk of hip and vertebral fractures. Pharmacologic treatment should continue for five years, during which time bone density monitoring should not be done. Menopausal estrogen therapy, menopausal estrogen plus progesterone, or raloxifene should not be used in women with osteoporosis. The decision

2017 American Academy of Family Physicians

62. Denosumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture

Denosumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture '); } else { document.write(' '); } ACE | Denosumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture Search > > Denosumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture - Denosumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture Published on 3 May 2017 Guidance Recommendations The Ministry (...) of Health’s Drug Advisory Committee has recommended: Denosumab 60 mg pre-filled syringe for the treatment of osteoporosis (T-score ≤ -2.5) in post-menopausal women at high risk of fracture, who: have a renal function eGFR > 30 ml/min, and are unable to tolerate or follow the administration instructions for oral bisphosphonates. Patients must also receive adequate calcium and vitamin D supplementation whilst undergoing treatment. Subsidy status Denosumab 60 mg pre-filled syringe is recommended

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

63. An overview and management of osteoporosis Full Text available with Trip Pro

An overview and management of osteoporosis Osteoporosis -related to various factors including menopause and aging- is the most common chronic metabolic bone disease, which is characterized by increased bone fragility. Although it is seen in all age groups, gender, and races, it is more common in Caucasians (white race), older people, and women. With an aging population and longer life span, osteoporosis is increasingly becoming a global epidemic. Currently, it has been estimated that more than (...) 200 million people are suffering from osteoporosis. According to recent statistics from the International Osteoporosis Foundation, worldwide, 1 in 3 women over the age of 50 years and 1 in 5 men will experience osteoporotic fractures in their lifetime. Every fracture is a sign of another impending one. Osteoporosis has no clinical manifestations until there is a fracture. Fractures cause important morbidity; in men, in particular, they can cause mortality. Moreover, osteoporosis results

2016 European journal of rheumatology

64. Cost-Effectiveness of Zoledronic Acid to Prevent and Treat Postmenopausal Osteoporosis in Comparison with Routine Medical Treatment Full Text available with Trip Pro

Cost-Effectiveness of Zoledronic Acid to Prevent and Treat Postmenopausal Osteoporosis in Comparison with Routine Medical Treatment Fractures caused by osteoporosis are prevalent among elderly females, which reduce quality of life significantly. This study aimed at comparing cost-effectiveness of Zoledronic acid in preventing and treating post-menopause osteoporosis as compared with routine medical treatment.This cost-effectiveness study was carried out retrospectively from the Ministry (...) fracture for a 36-month period were about 0.82, 0.57, and 1.06, respectively. Vertebral and hip fractures, and non-vertebral fractures or any clinical fracture for a 12-month period were calculated as 1.14 and 0.64, respectively. In other words, Zoledronic acid consumption approach is a cheaper and better approach based on an economic assessment, and it can be considered as a dominant approach.According to the cost-effectiveness of zoledronic acid in the prevention and treatment of osteoporosis

2016 Electronic physician

65. Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness

Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness | CADTH.ca Find the information you need Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Published on: December 12, 2016 Project Number: RC0829-000 Product Line: Research (...) Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the cost-effectiveness of denosumab versus zoledronic acid in patients with osteoporosis? Key Message Two studies were identified that evaluated the cost-effectiveness of denosumab for the treatment of elderly men with osteoporosis, from a payer perspective in the United States or Sweden. Both studies found that subcutaneous denosumab 60 mg administered once every six months was associated with lower-costs

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

66. Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines

Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines Published on: November 28, 2016 Project Number: RC0828-000 Product (...) Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of denosumab versus zoledronic acid in male patients with osteoporosis? What is the comparative clinical effectiveness of denosumab versus zoledronic acid in male patients with osteoporosis and non-metastatic prostate cancer receiving adjuvant anti-androgen therapy? What are the evidence-based guidelines regarding the use of denosumab and zoledronic acid

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

67. The Occurrence of Subclinical Hypercortisolism and Osteoporosis in Patients with Incidentally Discovered Unilateral and Bilateral Adrenal Tumors Full Text available with Trip Pro

The Occurrence of Subclinical Hypercortisolism and Osteoporosis in Patients with Incidentally Discovered Unilateral and Bilateral Adrenal Tumors Adrenal incidentalomas (AI) are clinically silent adrenal masses that are detected incidentally during imaging procedures performed for unrelated diseases. The aim of this study was to investigate the prevalence of sub-clinical hypercortisolism (SH) and associated co-morbidities in patients with unilateral AI (UAI) and bilateral AI (BAI).We evaluated (...) , and diabetes, hypertension and dyslipidemia occurred with similar frequency in both groups. The overall prevalence of SH was 20.5% based on post-1 mg DST, and 20.0% based on post-LDDST cortisol levels, and it was more prevalent in BAI than UAI patients (31.1% vs 15.2%, respectively, p=0.026). LS BMD was lower in BAI than in UAI patients (0.96±0.14 vs 0.87±0.15, p=0.002). There were no differences in FN BMD. The prevalence of osteoporosis was higher in BAI compared to UAI patients (37.1% vs 15.9

2016 Journal of medical biochemistry

68. Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Full Text available with Trip Pro

Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Calcium is the dominant mineral present in bone and a shortfall nutrient in the American diet. Supplements have been recommended for persons who do not consume adequate calcium from their diet as a standard strategy for the prevention of osteoporosis (...) and related fractures. Whether calcium with or without vitamin D supplementation is beneficial or detrimental to vascular health is not known.The National Osteoporosis Foundation and American Society for Preventive Cardiology convened an expert panel to evaluate the effects of dietary and supplemental calcium on cardiovascular disease based on the existing peer-reviewed scientific literature. The panel considered the findings of the accompanying updated evidence report provided by an independent evidence

2016 Annals of Internal Medicine

69. Love your bones: finding and treating osteoporosis

Love your bones: finding and treating osteoporosis Love your bones: finding and treating osteoporosis - Evidently Cochrane Search and hit Go By October 20, 2016 // Today is World Osteoporosis Day. We’re taking a look at the campaign and at Cochrane evidence on osteoporosis. Be proactive and #LoveYourBones is the message of this year’s . The campaign is a call to action for members of the public to act early to protect their bone and muscle health, and for health professionals and those who fund (...) health care to prioritize osteoporosis and fracture prevention by ensuring that people who are at high risk are assessed and offered appropriate treatment. People are also being asked to raise awareness of the campaign by wearing white, not a colour that does anything for me, so instead I’m blogging some Cochrane evidence. What is osteoporosis? Osteoporosis is a condition that weakens bones through a reduction in bone mineral density (BMD), making the risk of broken bones (fractures) more likely

2016 Evidently Cochrane

70. Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin Full Text available with Trip Pro

Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin Introduction. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Proper diagnosis of osteoporosis as a systemic adverse effect of COPD is of significant importance. The present study aimed at evaluating the prevalence of osteoporosis and its risk factors in men suffering from COPD in Qazvin (2014). Methods. This descriptive-analytical study was conducted on 90 patients (...) with COPD using random sampling. Anthropometric data and results from physical examination were collected. Pulmonary function test and bone mineral densitometry were done for all participants as well. Results. The prevalence of osteopenia and osteoporosis in COPD patients was 31.5 and 52.8 percent, respectively. Bone mineral density (BMD) at the femoral neck was associated significantly with body mass index (BMI), increased severity of COPD, and use of oral corticosteroid (P < 0.05). Conclusion

2016 International journal of chronic diseases

71. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. Full Text available with Trip Pro

Romosozumab Treatment in Postmenopausal Women with Osteoporosis. Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption.We enrolled 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck. Patients were randomly assigned to receive subcutaneous injections of romosozumab (at a dose of 210 mg) or placebo monthly for 12 months; thereafter, patients in each group received denosumab for 12 months (...) the transition to denosumab (0.6% [21 of 3325 patients] in the romosozumab group vs. 2.5% [84 of 3327] in the placebo group, a 75% lower risk with romosozumab; P<0.001). Adverse events, including instances of hyperostosis, cardiovascular events, osteoarthritis, and cancer, appeared to be balanced between the groups. One atypical femoral fracture and two cases of osteonecrosis of the jaw were observed in the romosozumab group.In postmenopausal women with osteoporosis, romosozumab was associated with a lower

2016 NEJM Controlled trial quality: uncertain

72. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor.To determine the efficacy and safety of abaloparatide, 80 μg, vs placebo for prevention of new vertebral fracture in postmenopausal women at risk of osteoporotic fracture.The Abaloparatide Comparator Trial (...) greater with abaloparatide than placebo (all P < .001). Incidence of hypercalcemia was lower with abaloparatide (3.4%) vs teriparatide (6.4%) (risk difference [RD], −2.96 [95%CI, −5.12 to −0.87]; P = .006). [table: see text].Among postmenopausal women with osteoporosis, the use of subcutaneous abaloparatide, compared with placebo, reduced the risk of new vertebral and nonvertebral fractures over 18 months. Further research is needed to understand the clinical importance of RD, the risks and benefits

2016 JAMA Controlled trial quality: predicted high

73. [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"]

[Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"] Systematische leitlinienrecherche und -bewertung sowie extraktion relevanter empfehlungen für ein DMP osteoporose: abschlussbericht; auftrag V14-0 [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"] Systematische leitlinienrecherche und -bewertung sowie extraktion relevanter empfehlungen für ein DMP (...) osteoporose: abschlussbericht; auftrag V14-0 [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

2016 Health Technology Assessment (HTA) Database.

74. Alendronic Acid / Colecalciferol Mylan - postmenopausal osteoporosis in women at risk of vitamin D deficiency

Alendronic Acid / Colecalciferol Mylan - postmenopausal osteoporosis in women at risk of vitamin D deficiency 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 24 June 2016 EMA/354096/2016 EMEA/H/C/004172 Questions and answers (...) Withdrawal of the marketing authorisation application for Alendronic Acid/Colecalciferol Mylan (alendronic acid and colecalciferol) On 27 May 2016, Mylan SAS officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Alendronic Acid/Colecalciferol Mylan, for the treatment of postmenopausal osteoporosis in women at risk of vitamin D deficiency. What is Alendronic Acid/Colecalciferol Mylan? Alendronic Acid

2016 European Medicines Agency - EPARs

75. Postmenopausal Osteoporosis. Full Text available with Trip Pro

Postmenopausal Osteoporosis. 27223157 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2096-7 10.1056/NEJMc1602599 Black Dennis M DM Rosen Clifford J CJ eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2095 27223158 N Engl J Med. 2016 May 26;374(21):2095-6 (...) 27223159 N Engl J Med. 2016 May 26;374(21):2096 27223160 Bone Density Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223157 10.1056/NEJMc1602599 10.1056/NEJMc1602599#SA4

2016 NEJM

76. Postmenopausal Osteoporosis. Full Text available with Trip Pro

Postmenopausal Osteoporosis. 27223158 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2095 10.1056/NEJMc1602599 Michaëlsson Karl K Uppsala University, Uppsala, Sweden karl.michaelsson@surgsci.uu.se. Aspenberg Per P Linköping University, Linköping, Sweden. eng 88225-1 CIHR Canada Letter Comment United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med (...) . 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2096-7 27223157 Bone Density Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223158 10.1056/NEJMc1602599 PMC5104560 CAMS6243 10.1056/NEJMc1602599#SA1 N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 BMJ. 2015 May 26;350:h2088 26013536 Osteoporos Int. 2016 Jan;27(1):417

2016 NEJM

77. Postmenopausal Osteoporosis. Full Text available with Trip Pro

Postmenopausal Osteoporosis. 27223159 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2095-6 10.1056/NEJMc1602599 Ott Susan M SM University of Washington, Seattle, WA smott@uw.edu. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2096-7 27223157 Bone Density (...) Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223159 10.1056/NEJMc1602599 10.1056/NEJMc1602599#SA2

2016 NEJM

78. Postmenopausal Osteoporosis. Full Text available with Trip Pro

Postmenopausal Osteoporosis. 27223160 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2096 10.1056/NEJMc1602599 Cheung Angela M AM University of Toronto, Toronto, ON, Canada angela.cheung@uhn.ca. Papaioannou Alexandra A McMaster's University, Hamilton, ON, Canada. Morin Suzanne S McGill University, Montreal, QC, Canada. Osteoporosis Canada Scientific Advisory Council eng Letter Comment United States N Engl J Med (...) 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2096-7 27223157 Bone Density Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223160 10.1056/NEJMc1602599 10.1056/NEJMc1602599#SA3

2016 NEJM

79. Relationships between serum Omentin-1 levels and bone mineral density in older men with osteoporosis Full Text available with Trip Pro

Relationships between serum Omentin-1 levels and bone mineral density in older men with osteoporosis To investigate the correlation between serum Omentin-1 levels and the presence of osteoporosis in older men.Serum Omentin-1, bone turnover biochemical markers, and bone mineral density (BMD) were determined in 45 older men with osteoporosis or 45 older men without osteoporosis (65-70 years old).Omentin-1 levels were increased in older men with osteoporosis, and the differences remained (...) with osteoporosis and control groups that were considered separately.Omentin-1 is an independent predictor of BMD in older men with osteoporosis, and it is negatively correlated with bone turnover biochemical markers. It is suggested that Omentin-1 may exert a negative effect on bone mass through the regulation of the osteoblast differentiation in the older men with osteoporosis.

2016 Chronic diseases and translational medicine

80. Osteoporosis Decision Aid

Osteoporosis Decision Aid Osteoporosis Decision Aid | Mayo Clinic Shared Decision Making National Resource Center Toggle navigation Osteoporosis Decision Aid The Osteoporosis Choice decision aid conveys the pros and cons of treatment It uses estimates of the patient's based on the FRAX calculator. Decision aids to be used during the encounter: interactive tool Printed version Decision aids in practice: Additional resources DISCLAIMER : No decision aid replaces the conversation patients should

2016 Washington Health Care Authority